Evoke Pharma, Inc. (EVOK) Reaches $2.17 52 Week Low; Hoplite Capital Management LP Has Lowered Microsoft (MSFT) Stake

February 15, 2018 - By Marguerite Chambers

Hoplite Capital Management Lp decreased Microsoft Corp (MSFT) stake by 1.54% reported in 2017Q3 SEC filing. Hoplite Capital Management Lp sold 23,860 shares as Microsoft Corp (MSFT)’s stock rose 4.75%. The Hoplite Capital Management Lp holds 1.53 million shares with $113.94 million value, down from 1.55M last quarter. Microsoft Corp now has $705.38B valuation. The stock increased 0.88% or $0.8 during the last trading session, reaching $91.61. About 11.55 million shares traded. Microsoft Corporation (NASDAQ:MSFT) has risen 34.52% since February 15, 2017 and is uptrending. It has outperformed by 17.82% the S&P500.

The stock of Evoke Pharma, Inc. (NASDAQ:EVOK) hit a new 52-week low and has $1.97 target or 9.00% below today’s $2.17 share price. The 5 months bearish chart indicates high risk for the $33.37M company. The 1-year low was reported on Feb, 15 by Barchart.com. If the $1.97 price target is reached, the company will be worth $3.00 million less. The stock decreased 10.91% or $0.265 during the last trading session, reaching $2.165. About 226,396 shares traded or 175.06% up from the average. Evoke Pharma, Inc. (NASDAQ:EVOK) has declined 51.99% since February 15, 2017 and is downtrending. It has underperformed by 68.69% the S&P500.

Among 9 analysts covering Evoke Pharma (NASDAQ:EVOK), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Evoke Pharma has $27 highest and $2 lowest target. $10.50’s average target is 384.99% above currents $2.165 stock price. Evoke Pharma had 19 analyst reports since August 20, 2015 according to SRatingsIntel. The stock of Evoke Pharma, Inc. (NASDAQ:EVOK) has “Buy” rating given on Monday, March 14 by Ascendiant Capital. The company was maintained on Wednesday, November 15 by FBR Capital. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 29. On Tuesday, October 24 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Evoke Pharma, Inc. (NASDAQ:EVOK) earned “Hold” rating by Noble Financial on Tuesday, July 19. Rodman & Renshaw maintained the shares of EVOK in report on Friday, December 23 with “Neutral” rating. The rating was initiated by Brean Capital with “Buy” on Thursday, August 20. The firm earned “Buy” rating on Monday, January 30 by Laidlaw. Rodman & Renshaw upgraded it to “Buy” rating and $6 target in Thursday, January 5 report. The firm has “Buy” rating given on Thursday, October 1 by H.C. Wainwright.

Analysts await Evoke Pharma, Inc. (NASDAQ:EVOK) to report earnings on March, 21. They expect $-0.22 earnings per share, down 22.22% or $0.04 from last year’s $-0.18 per share. After $-0.24 actual earnings per share reported by Evoke Pharma, Inc. for the previous quarter, Wall Street now forecasts -8.33% EPS growth.

Investors sentiment increased to 4.5 in 2017 Q3. Its up 3.00, from 1.5 in 2017Q2. It is positive, as 2 investors sold Evoke Pharma, Inc. shares while 0 reduced holdings. 4 funds opened positions while 5 raised stakes. 4.20 million shares or 123.21% more from 1.88 million shares in 2017Q2 were reported. Two Sigma Securities Limited Liability Corporation has 11,137 shares. Morgan Stanley reported 5,950 shares or 0% of all its holdings. Advisers Lc reported 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). Bank Of Ny Mellon Corporation reported 24,908 shares or 0% of all its holdings. Citigroup Inc accumulated 500 shares. Blackrock holds 0% or 62,369 shares in its portfolio. The California-based Wells Fargo & Commerce Mn has invested 0% in Evoke Pharma, Inc. (NASDAQ:EVOK). Vanguard Gru accumulated 0% or 523,650 shares. Knoll Management Limited Partnership reported 225,000 shares or 0.64% of all its holdings. State Treasurer State Of Michigan has invested 0.01% in Evoke Pharma, Inc. (NASDAQ:EVOK). Millennium invested in 0% or 54,853 shares. Commonwealth Equity stated it has 30,062 shares. Family Mgmt invested in 10,425 shares or 0.02% of the stock. Pnc Finance Group Incorporated has invested 0% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK). Geode Mngmt Lc holds 0% in Evoke Pharma, Inc. (NASDAQ:EVOK) or 23,048 shares.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company has market cap of $33.37 million. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. It currently has negative earnings.

Among 37 analysts covering Microsoft Corporation (NASDAQ:MSFT), 29 have Buy rating, 2 Sell and 6 Hold. Therefore 78% are positive. Microsoft Corporation had 167 analyst reports since July 22, 2015 according to SRatingsIntel. The firm earned “Sell” rating on Monday, September 25 by Jefferies. The firm has “Sell” rating given on Thursday, February 1 by Jefferies. The rating was maintained by Wunderlich with “Hold” on Friday, January 29. The stock has “Buy” rating by Tigress Financial on Monday, January 23. Cowen & Co maintained Microsoft Corporation (NASDAQ:MSFT) rating on Friday, January 26. Cowen & Co has “Buy” rating and $95.0 target. The firm has “Neutral” rating by Atlantic Securities given on Thursday, November 10. The firm has “Buy” rating given on Wednesday, August 23 by BMO Capital Markets. The firm has “Buy” rating by RBC Capital Markets given on Monday, May 29. The firm has “Hold” rating by J.P. Morgan given on Thursday, January 25. Canaccord Genuity maintained Microsoft Corporation (NASDAQ:MSFT) on Thursday, January 25 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marguerite Chambers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: